Eupraxia Pharmaceuticals Inc (EPRX) Stock Price, Quote & News

Company Profile

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and E...

Industry: Biotechnology

Sector: Healthcare

Phone: 250 590 3968

Website: www.eupraxiapharma.com

Address:

2067 Cadboro Bay Road, Suite 201, Victoria, Canada

jheerdink Apr. 2 at 2:48 AM

$EPRX https://youtu.be/qaYBCWlMTig?si=MxNy-xAojBXYgsmw

0 · Reply

jheerdink Mar. 31 at 7:45 PM

$EPRX Please join us as we are excited to kick off April with a powerful Tribe Public CEO Presentation & Q&A Webinar tomorrow, Wednesday, April 1 at 8:00am PT / 11:00am ET. The session is titled: "Turning EOE Into a Once-a-Year Appointment.” We’ll be joined by James A. Helliwell, M.D., Co-founder and CEO of Eupraxia Pharmaceuticals (NASDAQ: EPRX), who will deliver a short presentation followed by a focused 5–10 minute Q&A. This fast-moving, 30-minute format is designed so you can plug in, learn, and get back to your day with new insights. If you’ve already registered, you’re all set—just add it to your calendar and join us tomorrow. If you haven’t yet, register here today: http://Treat-EOE-Once-a-Year.TribePublic.com. You are also welcome to submit questions in advance for Dr. Helliwell at mailto:[email protected], or drop them directly into the Zoom chat during the event. Feel free to invite a colleague or friend who would value direct access.

0 · Reply

OfficialStocktwitsUser Mar. 31 at 4:51 PM

$EPRX RSI: 39.57, MACD: -0.3306 Vol: 0.46, MA20: 7.41, MA50: 8.04 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Quantumup Mar. 31 at 2:12 PM

Piper Sandler⬆️ $ANAB to $95/reitd Overweight. $GSK XBI FBRX ENTO TAK TEVA SNY AZN - AMGN BMY $EPRX PHAT Piper Sandler said in its note: ANAB has traded up ~190%+ (vs ~45%+ XBI) over the last year largely driven by the success of JEMPERLI's launch (partnered with GSK, not covered) and ANB033's (CD122 antagonist) opportunity in Celiac disease (CeD) and eosinophilic esophagitis (EoE). Hence, ahead of ANB033 Ph1b data in CeD (4Q26) and EoE (mid-2027), we answered 34 investor questions related to its mechanistic rationale in inflammatory disease, pre-clinical and clinical data, expectations ahead of data readouts, competitive landscape, and the regulatory path in both indications. Importantly, it is crucial to appreciate both indications represent blockbuster opportunities where nothing is approved in CeD and EoE has high remaining unmet need. Thus, we remain bullish on ANAB and believe ANB033 represents a significant value proposition. We updated our model, raising our PT to $95 (from $67).

0 · Reply

jheerdink Mar. 25 at 10:55 PM

$EPRX https://vistapglobal.com/eupraxias-ep-104-is-quietly-auditioning-for-a-starring-role-in-eosinophilic-esophagitis-eprx-sny-tak-ibb-xbi/

0 · Reply

PaulLaurent Mar. 25 at 7:31 AM

🚀📈 Top Gainers 📈🚀AH $NXTT $BRZE $EPRX $WTO $VIVO

0 · Reply

PaulLaurent Mar. 24 at 7:20 AM

🚀📈 Top Gainers 📈🚀AH $EEIQ $NTGR $PLSE $EPRX $EDBL

0 · Reply

Quantumup Mar. 23 at 11:26 AM

William Blair🏁 $EPRX and said:::We are initiating coverage of Eupraxia with an Outperform rating and fair value estimate of $14 per share. $BMY AZN - AMGN PHAT APGE PFE $CLDX Here's what else William Blair had to say: https://x.com/Quantumup1/status/2036041121407685083?s=20

0 · Reply

mikesterz7 Mar. 17 at 4:05 PM

$EPRX Keep buying

0 · Reply

Quantumup Mar. 17 at 12:05 PM

H.C. Wainwright⬇️ $EPRX $BMY AZN - AMGN $PHAT $APGE $CLDX H.C. Wainwright said—We reiterate our Buy rating on Eupraxia Pharmaceuticals (EPRX) and revise our price target to $11 (from $12) following the company's 4Q25 results and additional 52-week follow-up data from the RESOLVE trial evaluating EP-104Gl in eosinophilic esophagitis (EoE) While quarterly financials remain secondary for a clinical-stage company, the durability data continue to reinforce the differentiated profile of EP-104GI as a long-acting, localized steroid therapy, supporting the potential for infrequent dosing and improved adherence versus current treatment approaches Our price target revision reflects higher forward opex assumptions and dilution from the recent equity raise, partially offset by a higher probability of success for EP-104GI and a lower cost of capital in our model Importantly, the Phase 2b RESOLVE study remains on track for a 3Q26 topline readout, which we view as the next key catalyst for the program.

0 · Reply

Eupraxia Pharmaceuticals Boasts $900 Million Peak Sales Potential: Analyst

Thu, 12 Mar 2026 21:03:00 -0400 - 23 days ago

Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results

Feb 20, 2026, 3:10 PM EST - 6 weeks ago

Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option

Feb 19, 2026, 2:18 AM EST - 6 weeks ago

Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants

Feb 18, 2026, 4:01 PM EST - 6 weeks ago

Eupraxia Pharmaceuticals Announces Proposed Public Offering

Jan 8, 2026, 7:34 AM EST - 3 months ago

Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy

Nov 13, 2025, 5:00 PM EST - 5 months ago

Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results after Dosing with EP-104GI

Nov 4, 2025, 4:39 PM EST - 5 months ago

Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results

Sep 29, 2025, 5:00 PM EDT - 6 months ago

Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs

Sep 24, 2025, 8:54 AM EDT - 6 months ago

Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter Option

Sep 22, 2025, 10:42 PM EDT - 6 months ago

Eupraxia Pharmaceuticals Announces Pricing of US$70 Million Public Offering of Common Shares

Sep 22, 2025, 4:01 PM EDT - 6 months ago

Eupraxia Pharmaceuticals Announces Proposed Public Offering of Common Shares

Aug 12, 2025, 4:25 PM EDT - 8 months ago

Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 22, 2025, 5:17 PM EDT - 9 months ago

Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences

Jul 8, 2025, 7:00 AM EDT - 9 months ago

Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis

Jun 2, 2025, 6:30 PM EDT - 10 months ago

Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders

May 7, 2025, 2:00 PM EDT - 11 months ago

Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025

May 6, 2025, 6:00 PM EDT - 11 months ago

Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results

Apr 24, 2025, 5:00 PM EDT - 1 year ago

Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May

Mar 20, 2025, 5:31 PM EDT - 1 year ago

Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results

Feb 25, 2025, 7:00 AM EST - 1 year ago

Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Feb 18, 2025, 7:00 AM EST - 1 year ago

Eupraxia Pharmaceuticals Announces CFO Succession

Nov 20, 2024, 7:00 AM EST - 1 year ago

Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months

Nov 14, 2024, 5:00 PM EST - 1 year ago

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting

Nov 13, 2024, 5:00 PM EST - 1 year ago

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024

Nov 12, 2024, 5:56 PM EST - 1 year ago

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Nov 7, 2024, 5:00 PM EST - 1 year ago

Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results

Oct 31, 2024, 7:36 PM EDT - 1 year ago

Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million

Oct 28, 2024, 7:00 AM EDT - 1 year ago

Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024

Oct 15, 2024, 7:00 AM EDT - 1 year ago

Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis

Oct 10, 2024, 7:00 AM EDT - 1 year ago

Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024

Oct 2, 2024, 5:01 PM EDT - 1 year ago

Eupraxia Pharmaceuticals Strengthens Senior Management Team

Sep 19, 2024, 5:00 PM EDT - 1 year ago

Eupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal Diseases

Sep 11, 2024, 7:00 AM EDT - 1 year ago

Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Sep 4, 2024, 7:00 AM EDT - 1 year ago

Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 7, 2024, 5:00 PM EDT - 1 year ago

Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results

Aug 2, 2024, 7:00 AM EDT - 1 year ago

Eupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt Facility

Jul 8, 2024, 7:00 AM EDT - 1 year ago

Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo

Jul 3, 2024, 5:00 PM EDT - 1 year ago

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024

Jun 5, 2024, 7:00 AM EDT - 1 year ago

Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024

May 23, 2024, 5:00 PM EDT - 2 years ago

Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

May 22, 2024, 7:00 AM EDT - 2 years ago

Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024

May 21, 2024, 5:00 PM EDT - 2 years ago

Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

May 14, 2024, 7:00 AM EDT - 2 years ago

Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024

May 8, 2024, 5:03 PM EDT - 2 years ago

Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 2, 2024, 7:00 AM EDT - 2 years ago

Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board

Apr 11, 2024, 7:00 AM EDT - 2 years ago

Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024

Apr 8, 2024, 7:00 AM EDT - 2 years ago

Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference

Apr 5, 2024, 7:00 AM EDT - 2 years ago

Eupraxia Pharmaceuticals Begins Trading on Nasdaq Today

Apr 3, 2024, 5:00 PM EDT - 2 years ago

Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024

jheerdink Apr. 2 at 2:48 AM

$EPRX https://youtu.be/qaYBCWlMTig?si=MxNy-xAojBXYgsmw

0 · Reply

jheerdink Mar. 31 at 7:45 PM

0 · Reply

OfficialStocktwitsUser Mar. 31 at 4:51 PM

0 · Reply

Quantumup Mar. 31 at 2:12 PM

0 · Reply

jheerdink Mar. 25 at 10:55 PM

$EPRX https://vistapglobal.com/eupraxias-ep-104-is-quietly-auditioning-for-a-starring-role-in-eosinophilic-esophagitis-eprx-sny-tak-ibb-xbi/

0 · Reply

PaulLaurent Mar. 25 at 7:31 AM

🚀📈 Top Gainers 📈🚀AH $NXTT $BRZE $EPRX $WTO $VIVO

0 · Reply

PaulLaurent Mar. 24 at 7:20 AM

🚀📈 Top Gainers 📈🚀AH $EEIQ $NTGR $PLSE $EPRX $EDBL

0 · Reply

Quantumup Mar. 23 at 11:26 AM

0 · Reply

mikesterz7 Mar. 17 at 4:05 PM

$EPRX Keep buying

0 · Reply

Quantumup Mar. 17 at 12:05 PM

0 · Reply

mikesterz7 Mar. 17 at 11:56 AM

$EPRX The company’s EP-104GI showed remission rates of 59% at 12 weeks and up to 76% at 24 weeks.

0 · Reply

StocktwitsNews Mar. 17 at 11:50 AM

EPRX Stock On Retail Radar After Strong Remission Data In Digestive Disease Trial $EPRX https://stocktwits.com/news/equity/markets/eupraxia-eprx-stock-phase-2-data-remission-rates/cZ3E2OARIQx

0 · Reply

DonCorleone77 Mar. 17 at 11:14 AM

$EPRX Eupraxia Pharmaceuticals' esophagitis candidate shows symptom decrease Eupraxia Pharmaceuticals announced positive symptom data from patients in the two highest dose cohorts from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis. Sub-analyses of scores including at least 12 injections indicated that: at 12 weeks, 59% of patients achieved clinical remission; at 24 weeks, 76% of patients maintained clinical remission, and at 52 weeks, 67% of patients maintained clinical remission. At 24 weeks, dose cohort 9 showed a mean reduction of 4.0 points in SDI score where a reduction of 3.0 points is considered clinical remission. Comparison of histologic and symptom data from Cohort 8b versus Cohort 8 at 12 weeks demonstrated meaningfully improved outcomes due to improved drug delivery to the tissues associated with the appropriate catheter. No SAEs have been reported to date. EP-104GI has been well tolerated at all dose levels, including the highest dose of 8 mg/site.

0 · Reply

DARKP00L Mar. 17 at 11:05 AM

$EPRX 06:57 on Mar. 17 2026 HC Wainwright & Co. Maintains Buy on Eupraxia Pharmaceuticals, Lowers Price Target to $11 #tradeideas

0 · Reply

DARKP00L Mar. 17 at 10:59 AM

$EPRX 06:57 on Mar. 17 2026 HC Wainwright & Co. Maintains Buy on Eupraxia Pharmaceuticals, Lowers Price Target to $11 #tradeideas

0 · Reply

Quantumup Mar. 11 at 8:06 PM

Raymond James (a/o 3/9) reiterated $EPRX at a Strong Buy rating and an $18 PT. $REGN - SNY $APGE BMY $TAK AZN - AMGN $PHAT Raymond James said in its note: Following our recent initiation of coverage and investor discussions thereafter, we are circling back to recap our thesis on EPRX, which we believe has among the best 2026 risk/reward setups in our coverage universe into Phase 2b RESOLVE data for EP-104GI in EoE expected in 2H26. Reiterate Strong Buy. Here's what else Raymond James had to say:

0 · Reply

TeeWhy1 Mar. 4 at 7:43 PM

$EPRX keep climbing!!!!

0 · Reply

jheerdink Mar. 2 at 8:02 PM

$EPRX https://vistapglobal.com/eupraxia-steps-into-the-spotlight-aaaai-2026-puts-eoe-back-on-the-growth-map-eprx-sny-regn-ibb-xbi/

0 · Reply

Quantumup Feb. 24 at 12:48 PM

Bloom Burton🏁 $EPRX Buy/$14 $REGN - $SNY $TAK BMY AZN PFE $PHAT Here's what Bloom Burton said in its initiation report: https://x.com/Quantumup1/status/2026277237402538359?s=20

0 · Reply

Doozio Feb. 21 at 6:30 PM

$EPRX thursday 🐑 2ndry. 🐒🍌🧠⏰♾️

0 · Reply

OfficialStocktwitsUser Feb. 21 at 3:46 PM

$EPRX RSI: 52.81, MACD: 0.0703 Vol: 0.31, MA20: 8.48, MA50: 7.88 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

JakeRussell948 Feb. 21 at 5:41 AM

$EPRX Eupraxia Pharmaceuticals develops precision neurology therapies. Clinical milestones drive valuation. Early-stage risk is high.

0 · Reply

Market Cap	257.84M
Revenue (ttm)	0.00
Net Income (ttm)	-38.58M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	259,600
Avg Vol	235,288
Day's Range	N/A - N/A
Shares Out	35.96M
Stochastic %K	58%
Beta	1.55
Analysts	Strong Sell
Price Target	$14.84